Related Experiment Video

Updated: Jul 16, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Adagrasib's Efficacy Sustained in KRASG12C NSCLC

    Cancer Discovery
    |September 13, 2023
    PubMed

    Insights

    Adagrasib demonstrates lasting effectiveness and manageable safety in patients with advanced KRASG12C non-small cell lung cancer. This KRASG12C inhibitor offers durable efficacy, with about a third of patients alive at two years.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
    • KRAS mutations, particularly KRASG12C, are common drivers in NSCLC but historically lacked targeted therapies.

    Purpose of the Study:

    • To evaluate the long-term efficacy and safety of adagrasib, a KRASG12C inhibitor, in patients with previously treated advanced KRASG12C-mutated NSCLC.
    • To report on outcomes from the KRYSTAL-1 trial at a 2-year follow-up point.

    Main Methods:

    • KRYSTAL-1 is an ongoing clinical trial investigating adagrasib in patients with KRASG12C-mutated NSCLC.
    • Data presented are based on a 2-year follow-up, assessing overall survival and emergent toxicities.

    Main Results:

    • Adagrasib demonstrated durable efficacy in patients with advanced, previously treated KRASG12C NSCLC.
    • At the 2-year mark, approximately one-third of patients remained alive, indicating sustained treatment benefit.
    • No new unexpected toxicities were observed, suggesting a manageable long-term safety profile for adagrasib.

    Conclusions:

    • Adagrasib provides durable clinical benefit in patients with advanced KRASG12C NSCLC.
    • The long-term safety profile of adagrasib appears manageable, supporting its continued use in this patient population.

    More Related Videos

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    8.0K
    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    8.9K

    Related Concept Videos

    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a...
    6.3K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.8K